

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	1802	Leishmaniasis AND @ad<="20020527"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/10/19 17:07
S2	1	(Treatment NEAR4 Leismaniasis)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/10/19 17:10
S4	4	(Salvaggio A).IN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/10/19 17:12
S6	40	(Nicoletti F).IN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/10/19 17:14
S7	13	(Macri B).IN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/10/19 17:17

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/Caplus(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/Caplus enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/Caplus fields enhanced with simultaneous left and right
truncation
NEWS 8 SEP 25 CA(SM)/Caplus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new
classification scheme
NEWS 12 OCT 19 The Derwent World Patents Index suite of databases on STN will
be enhanced and reloaded on October 22, 2006
NEWS 13 OCT 19 LOGOFF HOLD duration extended to 120 minutes
NEWS 14 OCT 19 E-mail format enhanced

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:06:41 ON 20 OCT 2006

=> File Embase Medline CABA Biosis Caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.63

0.63

FILE 'EMBASE' ENTERED AT 09:08:26 ON 20 OCT 2006

Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 09:08:26 ON 20 OCT 2006

FILE 'CABA' ENTERED AT 09:08:26 ON 20 OCT 2006
COPYRIGHT (C) 2006 CAB INTERNATIONAL (CABI)

FILE 'BIOSIS' ENTERED AT 09:08:26 ON 20 OCT 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 09:08:26 ON 20 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s (treatment of Leishmaniasis)
2 FILES SEARCHED...

L1 614 (TREATMENT OF LEISHMANIASIS)

=> S Ubiquitin
L2 61316 UBIQUITIN

=> S (UK414 OR UK 114 OR UK-114 OR MFP114 OR MFP-114)
L3 42 (UK414 OR UK 114 OR UK-114 OR MFP114 OR MFP-114)

=> S (Pharmaceutical composition)
L4 39239 (PHARMACEUTICAL COMPOSITION)

=> S (Veterinary composition)
L5 324 (VETERINARY COMPOSITION)

=> S L1 AND L2
L6 1 L1 AND L2

=> D

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:971910 CAPLUS
DN 140:709
TI Use of UK114 in the treatment of leishmaniasis
IN Salvaggio, Antonio; Nicoletti, Pierferdinando; Macri, Battesimo
PA Pharmaproducts Uk Limited, UK
SO PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101477	A1	20031211	WO 2003-EP5551	20030527
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,				
	TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003238407	A1	20031219	AU 2003-238407	20030527
	EP 1511510	A1	20050309	EP 2003-732475	20030527
	EP 1511510	B1	20051012		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003011596	A	20050426	BR 2003-11596	20030527
	JP 2005529932	T2	20051006	JP 2004-508832	20030527
	AT 306279	E	20051015	AT 2003-732475	20030527

US 2006100142 A1 20060511 US 2005-516465 20051004
PRAI IT 2002-MI1205 A 20020604
WO 2003-EP5551 W 20030527
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D His

(FILE 'HOME' ENTERED AT 09:06:41 ON 20 OCT 2006)

FILE 'EMBASE, MEDLINE, CABA, BIOSIS, CAPLUS' ENTERED AT 09:08:26 ON 20 OCT 2006

L1 614 S (TREATMENT OF LEISHMANIASIS)
L2 61316 S UBIQUITIN
L3 42 S (UK414 OR UK 114 OR UK-114 OR MFP114 OR MFP-114)
L4 39239 S (PHARMACEUTICAL COMPOSITION)
L5 324 S (VETERINARY COMPOSITION)
L6 1 S L1 AND L2

=> S L1 AND L3
L7 0 L1 AND L3

=> S L3 AND L4
L8 2 L3 AND L4

=> D 1-2 IBIB All

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:387275 CAPLUS
DOCUMENT NUMBER: 140:380671
TITLE: Antitumor combinations comprising proteins and
chemotherapeutics
INVENTOR(S): Bartorelli, Alberto; Concas, Daniela; Archai, Chirra
Adalberto; Mor, Carlo
PATENT ASSIGNEE(S): Zetesis S.P.A., Italy
SOURCE: PCT Int. Appl., 9 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039393	A1	20040513	WO 2003-EP11912	20031027
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003285304	A1	20040525	AU 2003-285304	20031027
BR 2003015813	A	20050920	BR 2003-15813	20031027
CN 1708315	A	20051214	CN 2003-80102465	20031027
PRIORITY APPLN. INFO.:			IT 2002-MI2307	A 20021030
			WO 2003-EP11912	W 20031027

AN 2004:387275 CAPLUS
DN 140:380671
ED Entered STN: 13 May 2004
TI Antitumor combinations comprising proteins and chemotherapeutics

IN Bartorelli, Alberto; Concas, Daniela; Archai, Chirra Adalberto; Mor, Carlo
 PA Zetesis S.P.A., Italy
 SO PCT Int. Appl., 9 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K038-17
 ICS A61P035-00
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2004039393	A1	20040513	WO 2003-EP11912	20031027	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	AU 2003285304	A1	20040525	AU 2003-285304	20031027	
	BR 2003015813	A	20050920	BR 2003-15813	20031027	
	CN 1708315	A	20051214	CN 2003-80102465	20031027	
PRAI	IT 2002-MI2307	A	20021030			
	WO 2003-EP11912	W	20031027			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004039393	ICM	A61K038-17
	ICS	A61P035-00
	IPCI	A61K0038-17 [ICM,7]; A61P0035-00 [ICS,7]
	IPCR	A61K0035-37 [I,C*]; A61K0035-407 [I,A]; A61K0038-17 [I,A]; A61K0038-17 [I,C*]
	ECLA	A61K035/407; A61K035/407+M; A61K038/17A2; A61K038/17A2+M
AU 2003285304	IPCI	A61K0038-17 [ICM,7]; A61P0035-00 [ICS,7]
BR 2003015813	IPCI	A61K0038-17 [ICM,7]; A61P0035-00 [ICS,7]
	IPCR	A61K0035-37 [I,C*]; A61K0035-407 [I,A]; A61K0038-17 [I,A]; A61K0038-17 [I,C*]
CN 1708315	IPCI	A61K0038-17 [ICM,7]; A61P0035-00 [ICS,7]

AB Pharmaceutical comps. containing: (a) goat liver perchloric extract containing the protein UK 114, (b) cyclophosphamide; (c) doxorubicin or other anthracyclins; (d) 5-fluorouracil, in the form of a combination for the simultaneous, separated or sequential use in chemotherapy.

ST antitumor UK114 protein cyclophosphamide doxorubicin fluorouracil

IT Proteins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (UK 114; antitumor combinations comprising proteins and chemotherapeutics)

IT Antitumor agents

Chemotherapy

(antitumor combinations comprising proteins and chemotherapeutics)

IT Mammary gland, neoplasm

(carcinoma; antitumor combinations comprising proteins and chemotherapeutics)

IT Carcinoma

(mammary; antitumor combinations comprising proteins and chemotherapeutics)

IT Liver

(perchloric extract of goat; antitumor combinations comprising proteins and chemotherapeutics)

IT Capra
(perchloric extract of liver of; antitumor combinations comprising
proteins and chemotherapeutics)
IT 50-18-0, Cyclophosphamide 51-21-8, 5-Fluorouracil 23214-92-8,
Doxorubicin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor combinations comprising proteins and chemotherapeutics)

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:565925 CAPLUS
DOCUMENT NUMBER: 131:189725
TITLE: Oral compositions at low dosage of cytotoxic proteins
INVENTOR(S): Bartorelli, Alberto; Santi, Cesare
PATENT ASSIGNEE(S): Zetesis S.P.A., Italy
SOURCE: PCT Int. Appl., 8 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943340	A1	19990902	WO 1999-EP1068	19990218
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1298442	B1	20000110	IT 1998-MI356	19980224
CA 2321717	AA	19990902	CA 1999-2321717	19990218
AU 9926244	A1	19990915	AU 1999-26244	19990218
EP 1061938	A1	20001227	EP 1999-906246	19990218
EP 1061938	B1	20011114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 208627	E	20011115	AT 1999-906246	19990218
JP 2002504517	T2	20020212	JP 2000-533136	19990218
ES 2165727	T3	20020316	ES 1999-906246	19990218
PT 1061938	T	20020429	PT 1999-906246	19990218
PRIORITY APPLN. INFO.:			IT 1998-MI356	A 19980224
			WO 1999-EP1068	W 19990218

AN 1999:565925 CAPLUS
DN 131:189725
ED Entered STN: 08 Sep 1999
TI Oral compositions at low dosage of cytotoxic proteins
IN Bartorelli, Alberto; Santi, Cesare
PA Zetesis S.P.A., Italy
SO PCT Int. Appl., 8 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K038-16
ICS A61K038-17; A61K009-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9943340	A1	19990902	WO 1999-EP1068	19990218
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				

DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
 KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
 MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
 TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

IT 1298442	B1	20000110	IT 1998-MI356	19980224
CA 2321717	AA	19990902	CA 1999-2321717	19990218
AU 9926244	A1	19990915	AU 1999-26244	19990218
EP 1061938	A1	20001227	EP 1999-906246	19990218
EP 1061938	B1	20011114		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI

AT 208627	E	20011115	AT 1999-906246	19990218
JP 2002504517	T2	20020212	JP 2000-533136	19990218
ES 2165727	T3	20020316	ES 1999-906246	19990218
PT 1061938	T	20020429	PT 1999-906246	19990218

PRAI IT 1998-MI356	A	19980224		
WO 1999-EP1068	W	19990218		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9943340	ICM	A61K038-16
	ICS	A61K038-17; A61K009-00
	IPCI	A61K0038-16 [ICM,6]; A61K0038-17 [ICS,6]; A61K0009-00 [ICS,6]
	IPCR	A61K0009-00 [N,A]; A61K0009-00 [N,C*]; A61K0038-16 [I,A]; A61K0038-16 [I,C*]; A61K0038-17 [I,A]; A61K0038-17 [I,C*]
IT 1298442	ECLA	A61K038/16; A61K038/17A2
	IPCI	A61K [ICM,4]
	IPCR	A61K0009-00 [N,A]; A61K0009-00 [N,C*]; A61K0038-16 [I,A]; A61K0038-16 [I,C*]; A61K0038-17 [I,A]; A61K0038-17 [I,C*]
CA 2321717	IPCI	A61K0038-16 [ICM,6]; A61K0009-00 [ICS,6]; A61K0038-17 [ICS,6]
AU 9926244	IPCI	A61K0038-16 [ICM,6]; A61K0038-17 [ICS,6]; A61K0009-00 [ICS,6]
	IPCR	A61K0009-00 [N,A]; A61K0009-00 [N,C*]; A61K0038-16 [I,A]; A61K0038-16 [I,C*]; A61K0038-17 [I,A]; A61K0038-17 [I,C*]
EP 1061938	IPCI	A61K0038-16 [ICM,6]; A61K0038-17 [ICS,6]; A61K0009-00 [ICS,6]
	IPCR	A61K0009-00 [N,A]; A61K0009-00 [N,C*]; A61K0038-16 [I,A]; A61K0038-16 [I,C*]; A61K0038-17 [I,A]; A61K0038-17 [I,C*]
AT 208627	IPCI	A61K0038-16 [ICM,7]; A61K0038-17 [ICS,7]; A61K0009-00 [ICS,7]
	IPCR	A61K0009-00 [N,A]; A61K0009-00 [N,C*]; A61K0038-16 [I,A]; A61K0038-16 [I,C*]; A61K0038-17 [I,A]; A61K0038-17 [I,C*]
JP 2002504517	IPCI	A61K0038-00 [ICM,7]; A61K0009-08 [ICS,7]; A61K0009-16 [ICS,7]; A61K0009-20 [ICS,7]; A61P0035-00 [ICS,7]
	IPCR	A61K0009-00 [N,A]; A61K0009-00 [N,C*]; A61K0038-16 [I,A]; A61K0038-16 [I,C*]; A61K0038-17 [I,A]; A61K0038-17 [I,C*]
ES 2165727	IPCI	A61K0038-16 [ICM,7]; A61K0038-17 [ICS,7]; A61K0009-00 [ICS,7]
	IPCR	A61K0009-00 [N,A]; A61K0009-00 [N,C*]; A61K0038-16 [I,A]; A61K0038-16 [I,C*]; A61K0038-17 [I,A]; A61K0038-17 [I,C*]
PT 1061938	IPCI	A61K0038-16 [ICM,7]; A61K0038-17 [ICS,7]; A61K0009-00 [ICS,7]

IPCR A61K0009-00 [N,A]; A61K0009-00 [N,C*]; A61K0038-16
[I,A]; A61K0038-16 [I,C*]; A61K0038-17 [I,A];
A61K0038-17 [I,C*]

AB Pharmaceutical compns. for the oral and sublingual
administration containing proteins extractable from mammalian liver. Such
proteins include the proteins UK101 and UK114 and described in WO 92/10197
and WO 96/02567 as well as ubiquitin. Patients suffering from tumors in
advanced phase were treated for 30 days with 5-20 drops/day of 10-6M UK101
an 1% hydroalcoholic solution of ethanol. There was a 70% improvement in the
subjective conditions of the patients, particularly a decrease in the
painful symptomatol. and a decrease in the tumor mass in 20% of the cases.

ST oral pharmaceutical antitumor cytotoxic protein; UK101 antitumor cytotoxic
protein oral pharmaceutical; UK114 antitumor cytotoxic protein oral
pharmaceutical

IT Drug delivery systems
(drops; oral compns. at low dosage of cytotoxic proteins)

IT Envelope proteins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(gene env, UK 101 and UK 114; oral compns. at low
dosage of cytotoxic proteins)

IT Drug delivery systems
(granules; oral compns. at low dosage of cytotoxic proteins)

IT Cytotoxic agents
(oral compns. at low dosage of cytotoxic proteins)

IT Proteins, general, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(oral compns. at low dosage of cytotoxic proteins)

IT Drug delivery systems
(oral; oral compns. at low dosage of cytotoxic proteins)

IT Proliferation inhibition
(proliferation inhibitors; oral compns. at low dosage of cytotoxic
proteins)

IT Drug delivery systems
(sublingual; oral compns. at low dosage of cytotoxic proteins)

IT Drug delivery systems
(tablets, sublingual; oral compns. at low dosage of cytotoxic proteins)

IT 60267-61-0, Ubiquitin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(oral compns. at low dosage of cytotoxic proteins)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bartorelli, A; WO 9210197 A 1992 CAPLUS
- (2) Laboratoire Francais De Specialites Physiologiques Et Hygieniques; GB
989826 A 1965
- (3) Zetesis S P A; WO 9602567 A 1996 CAPLUS

=> D his

(FILE 'HOME' ENTERED AT 09:06:41 ON 20 OCT 2006)

FILE 'EMBASE, MEDLINE, CABA, BIOSIS, CAPLUS' ENTERED AT 09:08:26 ON 20
OCT 2006

L1 614 S (TREATMENT OF LEISHMANIASIS)
L2 61316 S UBIQUITIN
L3 42 S (UK414 OR UK 114 OR UK-114 OR MFP114 OR MFP-114)
L4 39239 S (PHARMACEUTICAL COMPOSITION)
L5 324 S (VETERINARY COMPOSITION)
L6 1 S L1 AND L2

L7 0 S L1 AND L3
L8 2 S L3 AND L4

=> S L3 AND L5
L9 . 0 L3 AND L5

=>